



Agonists and antagonists induce different palonosetron dissociation rates in 5-HT_{3A} and 5-HT_{3AB} receptors

Sarah C.R. Lummis*, Andrew J. Thompson

Department of Biochemistry, University of Cambridge, Tennis Court Road, Cambridge CB2 1QW, UK

ARTICLE INFO

Article history:

Received 3 January 2013

Received in revised form

19 April 2013

Accepted 8 May 2013

Keywords:

Serotonin receptor

Allosteric binding site

Site-directed mutagenesis

Radioligand binding

FlexStation assays

ABSTRACT

Palonosetron is a potent 5-HT₃ receptor antagonist with a unique structure and some unusual properties. Here we explore the properties of palonosetron at heterologously expressed 5-HT_{3A} and 5-HT_{3AB} receptors. We used receptors expressed in HEK293 cells, and functionally analysed them using a membrane potential sensitive dye in a Flexstation, which revealed IC₅₀s of 0.24 nM and 0.18 nM for 5-HT_{3A} and 5-HT_{3AB} receptors respectively. Radioligand binding studies with [³H]palonosetron revealed similar K_ds: 0.34 nM for 5-HT_{3A} and 0.15 nM for 5-HT_{3AB} receptors. Kinetic studies showed palonosetron association and dissociation rates were slightly faster in 5-HT_{3AB} than 5-HT_{3A} receptors, and for both subtypes dissociation rates were ligand-dependent, with antagonists causing more rapid dissociation than agonists. Similar ligand effects were not observed for [³H]granisetron dissociation studies. These data support previous studies which show palonosetron has actions distinct to other 5-HT₃ receptor antagonists, and the slow rates observed for agonist induced dissociation (*t*_{1/2} > 10 h) could at least partly explain the long duration of palonosetron effects *in vivo*.

© 2013 The Authors. Published by Elsevier Ltd. Open access under [CC BY license](http://creativecommons.org/licenses/by/3.0/).

1. Introduction

5-HT₃ receptors are members of the Cys-loop family of ligand-gated ion channels, membrane proteins that are responsible for fast excitation and inhibitory synaptic neurotransmission in central and peripheral nervous systems, and the targets for a number of important therapeutics. 5-HT₃ receptor antagonists are routinely used in the management of post-operative, radiotherapy-induced and chemotherapy-induced nausea and vomiting and for treating irritable bowel syndrome in patients that do not respond adequately to conventional therapies. A range of other therapeutic applications has also been suggested (reviewed in (Thompson and Lummis, 2007; Walstab et al., 2010)). Antagonists are often referred to as the “setrons”, and include ondansetron, granisetron and palonosetron (Fig. 1). These drugs are potent (*K*_d = nM – pM), long lived *in vivo*, and most are highly selective for the 5-HT₃ receptor.

Furthermore, they are usually well tolerated and display only mild, transient side-effects, making them the preferred choice of drug in most instances (Aapro, 2004; Blower, 1995; Eglen et al., 1995; Hirata et al., 2007).

Palonosetron has a different structure from the other 5-HT₃ antagonists (Fig. 1), and some distinctive properties. The first published accounts of these properties were in 1995, when radioligand binding experiments demonstrated that it bound to 5-HT₃ receptors with high potency and selectivity, and *in vivo* data showed an anti-emetic efficacy greater than or equal to that of ondansetron or granisetron (Bonhaus et al., 1995; Eglen et al., 1995; Wong et al., 1995). At that time, however, it was not clear that there are multiple 5-HT₃ receptor subunits, (A–E), in addition to alternative splice variants, thus providing the potential for a wide range of different 5-HT₃ receptor subtypes. Heteromeric assemblies of 5-HT_{3A} plus 5-HT_{3C}, 5-HT_{3D} or 5-HT_{3E} subunits have not yet been extensively studied, but their biophysical properties appear similar to homomeric 5-HT_{3A} receptors (see (Niesler, 2011) and (Walstab et al., 2010) for reviews). 5-HT_{3AB} receptors, however, have been extensively investigated in heterologous systems, and have differing concentration–response curves (increased *EC*₅₀ values and shallower Hill slopes), increased single channel conductance (5-HT_{3A} = sub-pS; 5-HT_{3AB} = 16–30 pS), an increased rate of desensitisation, reduced Ca²⁺ permeability and a non-linear current–voltage relationship (Davies et al., 1999; Kelley et al., 2003;

Abbreviations: 5-HT, 5-hydroxytryptamine (serotonin); HEK, human embryonic kidney; IC₅₀, concentration of antagonist required for half-maximal inhibition; *K*_d, affinity constant.

* Corresponding author. Tel.: +44 1223 765950; fax: +44 1223 333345.

E-mail address: sl120@cam.ac.uk (S.C.R. Lummis).




Fig. 1. Chemical structures of 5-HT and clinically used 5-HT₃ receptor competitive antagonists.

Livesey et al., 2008). To determine if there are differences in the affinity and association and dissociation rates of palonosetron in 5-HT_{3A} and 5-HT_{3AB} receptors, we here explore the effects of palonosetron on 5-HT₃ receptor function and binding in these receptor subtypes.

2. Materials and methods

2.1. Materials

All cell culture reagents were obtained from Gibco BRL (Paisley, U.K.), except foetal calf serum which was from Labtech International (Ringmer, U.K.). [³H]granisetron (84 Ci mmol⁻¹) was from PerkinElmer (Boston, Massachusetts, USA). [³H]palonosetron (37.2 Ci/mmol) was custom synthesised for Helsinn Healthcare (Lugano, Switzerland), and both this and the unlabelled form of palonosetron were kindly gifted by Helsinn Healthcare (Lugano, Switzerland). All other reagents were of the highest obtainable grade.

2.2. Cell culture and transfection

Human embryonic kidney (HEK) 293 cells were maintained on 90 mm tissue culture plates at 37 °C and 7% CO₂ in a humidified atmosphere. They were cultured in DMEM:F12 (Dulbecco's Modified Eagle Medium/Nutrient Mix F12 (1:1)) with GlutaMAX™ I media containing 10% foetal calf serum and passaged when confluent. For radioligand binding studies cells in 90 mm dishes were transfected using PEI and incubated for 3–4 days before use. For functional studies cells were plated on 96 well plates, transfected using the Neon transfection system (Invitrogen) and incubated 1–2 days before assay. Mutagenesis reactions were performed using QuikChange (Agilent Technologies Inc., CA, USA) using human 5-HT_{3A} or 5-HT_{3B} receptor subunit cDNA (accession numbers: P46098 or O95264) in pcDNA3.1 (Invitrogen, Paisley, UK). Subunit numberings have been altered to the aligning residues in the mouse 5-HT_{3A} receptor.




Fig. 2. Typical Flexstation responses of HEK293 cells expressing 5-HT_{3A} and 5-HT_{3AB} receptors. 5-HT at various concentrations (0–30 μM) was added at 20 s. Note the shapes of the responses, which are different in homomeric and heteromeric receptors. F = arbitrary fluorescent units.

2.3. Radioligand binding

Methods were as previously described (Lummis et al., 1993), with minor modifications. Briefly, transfected HEK293 cells were washed twice with phosphate buffered saline (PBS) at room temperature and scraped into 1 ml of ice-cold HEPES buffer (10 mM, pH 7.4) containing the following proteinase inhibitors (PI): 1 mM EDTA, 50 μg ml⁻¹ soybean trypsin inhibitor, 50 μg/ml bacitracin and 0.1 mM phenylmethylsulphonyl fluoride. Cells were homogenised, freeze-thawed, washed with HEPES buffer, and 50 μg of the crude cell membrane preparation incubated in 0.5 ml HEPES buffer containing [³H]granisetron or [³H]palonosetron at a range of concentrations for saturation binding, or at 0.3 nM and 0.1 nM respectively for competition binding and association/dissociation studies. Non-specific binding was determined using 10 μM quipazine. Equilibrium reactions were incubated for at least 1 h or 24 h for [³H]granisetron or [³H]palonosetron respectively at 4 °C. Dissociation was initiated with unlabelled ligands to give a final concentrations of 100 μM (5-HT), 10 μM (quipazine), 1 μM (MDL72222) or 100 nM (palonosetron). All samples were terminated by vacuum filtration using a Brandel cell harvester onto GF/B filters pre-soaked in 0.3% polyethyleneimine. Radioactivity was determined by scintillation counting using a Beckman LS6000SC (Fullerton, California, USA).

2.4. Fluorescent studies

These were performed as previously described (Price and Lummis, 2005). Briefly, cells were gently rinsed twice with buffer (10 mM HEPES, 115 mM NaCl, 1 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM glucose, pH 7.4) and 100 μl fluorescent membrane-potential sensitive dye (Molecular Devices) added. Cells were then incubated at room temperature for 45 min before assay. For inhibition studies, palonosetron was added either with the dye, ensuring a 45 min pre-incubation, or simultaneously with 5-HT (co-application). Fluorescence was measured in a FLEXstation™ (Molecular Devices Ltd., Wokingham, UK) every 2 s for 200 s using the acquisition software SOFTmax™ PRO v4.3. Control (buffer alone) or 5-HT (0.001 μM–30 μM) was added to each well at 20 s. Typical responses are shown in Fig. 2.

2.5. Data analysis

Data were analysed by iterative curve fitting using Prism software (GraphPad, San Diego, California, USA). Determination of K_i values was performed using the Cheng–Prusoff equation. Values are presented as mean ± SEM, n = 3–6.

3. Results

3.1. Functional studies

Examination of palonosetron inhibition of 5-HT₃ receptors expressed in oocytes revealed very slow recovery after washout, with <10% of the original response being recovered after a 10 min wash (data not shown). We therefore determined the inhibitory effects of palonosetron on 5-HT-induced responses using 5-HT₃ receptors expressed in HEK293 cells loaded with membrane sensitive fluorescent dye where washout is not required. Preliminary experiments revealed palonosetron required at least 5 min incubation before application of 5-HT to reveal its full inhibition, and thereafter it was preincubated for 45 min. Data revealed different apparent potencies of palonosetron at 5-HT_{3A} receptors, depending upon whether it was preincubated (pIC₅₀ = 9.73 ± 0.13;




Fig. 3. Inhibition of 5-HT-induced responses in HEK293 cells. A: Palonosetron is more potent when pre-applied (○) than when co-applied (◼) with 5-HT; example in cells expressing 5-HT_{3A} receptors. B: Palonosetron has similar IC₅₀s at 5-HT_{3A} and 5-HT_{3AB} receptors. Parameters derived from these data are given in Section 3.1.

IC₅₀ = 0.18 nM, *n* = 4) or co-applied with 5-HT (pIC₅₀ = 7.08 ± 0.14; IC₅₀ = 83 nM, *n* = 4), suggesting that palonosetron has a relatively slow on rate, and in particular that its on rate is slower than that of 5-HT (Fig. 3A).

With a 45 min preincubation, palonosetron inhibition of 5-HT-induced responses (Fig. 3B) revealed sub-nanomolar IC₅₀s at both 5-HT_{3A} and 5-HT_{3AB} receptors: pIC₅₀ = 9.61 ± 0.13; (IC₅₀ = 0.24 nM), and 9.73 ± 0.27; (IC₅₀ = 0.18 nM) respectively (*n* = 4).

Examination of 5-HT concentration response curves in the presence of 0, 0.1 nM or 0.3 nM palonosetron revealed increased EC₅₀s and decreased maximal responses with increasing palonosetron concentrations (Fig. 4).

3.2. Radioligand binding

Palonosetron displacement of the 5-HT₃-specific ligand [³H] granisetron revealed similar potencies at 5-HT_{3A} and 5-HT_{3AB} receptors. pIC₅₀s = 9.22 ± 0.05; (IC₅₀ = 0.60 nM; K_i = 0.3 nM), and 9.14 ± 0.18 (IC₅₀ = 0.71 nM; K_i = 0.35 nM) respectively. Saturation

experiments with a range of [³H]palonosetron concentrations revealed high affinity binding with K_d values of 0.34 ± 0.04 and 0.15 ± 0.04 nM at 5-HT_{3A} and 5-HT_{3AB} receptors respectively. Typical data is shown in Fig. 4.

3.3. Association and dissociation rates

Association of [³H]palonosetron was complete in ~30 min at both 5-HT_{3A} and 5-HT_{3AB} receptors, with *t*_{1/2} values of 4.1 (*k* = 0.16 ± 0.03) and 2.0 min (*k* = 0.35 ± 0.06) respectively (significantly different, *t*-test, *p* < 0.05). This is slower than previously reported where association was complete in under 10 min (Wong et al., 1995).

Our dissociation rates were also slower than previously reported, and were also strongly dependent on the ligand used for dissociation. An excess of unlabelled palonosetron gave *t*_{1/2} values for dissociation of 1.5 h and 1.0 h for 5-HT_{3A} and 5-HT_{3AB} receptors respectively, with values of 2.3 h and 1.7 h when an excess of MDL72222 was used. However when the agonists 5-HT or quipazine were used, *t*_{1/2} values were >10 h. Data are shown in Table 1




Fig. 4. Functional and radioligand binding data suggest similar effects of palonosetron at 5-HT_{3A} and 5-HT_{3AB} receptors. Top: Typical Flexstation data from 5-HT_{3A} and 5-HT_{3AB} receptor-expressing cells; EC₅₀ values increase and F_{max} values decrease as [palonosetron] increases. In this typical example EC₅₀s are 0.16 μM, 0.35 μM and 0.97 μM with relative F_{max} values of 100%, 70% and 40% for 0, 0.1 nM and 0.3 nM palonosetron in 5-HT_{3A} receptors, and 0.12 μM (100%), 0.27 μM (62%) and 1.6 μM (28%) in 5-HT_{3AB} receptors. Lower panel: typical radioligand binding curves for 5-HT_{3A} and 5-HT_{3AB} receptors.

Table 1

[³H] palonosetron and [³H] granisetron binding dissociation rates with different displacing ligands using 5-HT₃ receptors expressed in HEK293 cells.* = significantly different to 5-HT_{3A} receptors, *t*-test, *p* < 0.05.

	5-HT _{3A} receptors		5-HT _{3AB} receptors	
	k ₋₁ (mean ± S.E.M)	t _{1/2} (h)	k ₋₁ (mean ± S.E.M)	t _{1/2} (h)
[³H] palonosetron				
5-HT	0.032 ± 0.005	21.9	0.057 ± 0.008*	12.1
Quipazine	0.056 ± 0.003	12.5	0.068 ± 0.003*	10.1
MDL72222	0.29 ± 0.03	2.3	0.41 ± 0.04*	1.7
Palonosetron	0.44 ± 0.05	1.5	0.68 ± 0.08*	1.0
[³H] granisetron				
5-HT	0.14 ± 0.020	4.6	0.17 ± 0.023	4.0
MDL72222	0.15 ± 0.023	4.8	0.16 ± 0.021	4.2

with example curves in Fig. 5. These reveal that in the presence of agonists specific binding does not approach background levels until 2–5 days after dissociation is initiated. Similar experiments using [³H]granisetron revealed no differences in rates using agonists or antagonists (Table 1 and Fig. 6).

4. Discussion

Palonosetron is a potent 5-HT₃ receptor antagonist which is proving to be superior to other 5-HT₃ receptor antagonists for the treatment of acute and delayed post-operative, radiotherapy-induced and chemotherapy-induced nausea and vomiting. The unusual properties of palonosetron, which have been proposed to explain its superiority, include allosteric interactions, positive cooperativity and palonosetron-triggered 5-HT₃ receptor internalization (Rojas et al., 2008, 2010). Internalization was not explored in our association and dissociation rate experiments, as this process would not occur at the temperatures at which these experiments were performed, but the slow palonosetron dissociation rate shown here could provide an additional or alternative explanation to internalization: our data show palonosetron has the ability to

inhibit 5-HT₃ receptors for considerably longer than the more established 5-HT₃ receptor antagonists such as ondansetron and granisetron, which could result in a prolonged anti-emetic behaviour.

Palonosetron is a potent inhibitor of 5-HT-induced increases in fluorescence of a membrane potential sensitive dye. Inhibition of 5-HT₃ receptor function at low concentrations was expected as palonosetron has an affinity for 5-HT₃ receptors that is greater than other commonly used 5-HT₃ receptor antagonists (e.g. NG108-15 cells *K_d* = 0.05 nM (Wong et al., 1995), human hippocampus *K_d* = 0.15 nM (Wong et al., 1995), transfected HEK293 cells *K_d* = 0.2 nM (Rojas et al., 2008)). The slow dissociation rates we observed (*t*_{1/2} = 1–22 h) differ from previous studies (*t*_{1/2} = 8–10 min) (Wong et al., 1995), but are consistent with the slow recovery from palonosetron-induced 5-HT₃ receptor inhibition we observed in our preliminary experiments in oocytes, which precluded us from using them in this study. Somewhat similar data were observed by Rojas et al. (2008), who showed that 53 ± 11% of [³H]palonosetron remained associated with 5-HT₃ receptor-expressing HEK293 cells after a 2.5 h wash. This is akin to our data: e.g. dissociation of [³H]palonosetron from 5-HT_{3A} receptors in the presence of MDL72222 resulted in 67 ± 7% (*n* = 4) of [³H]palonosetron remaining after 2 h. Subsequent experiments by Rojas et al. (2010) suggested a difference between cells and cell-free membranes, with 65% [³H]palonosetron remaining in cells after a 60 min wash, but only 2% remaining in a cell-free membrane preparation (Rojas et al., 2010). Our preparation is similar to their cell free preparation, (i.e. it does not contain whole cells) although it is not washed as extensively, and our cells were not treated with trypsin; thus it may be that the different procedures can significantly effect binding characteristics.

We did not observe any major difference between the effects of palonosetron at homomeric (5-HT_{3A}) and heteromeric (5-HT_{3AB}) receptors. 5-HT_{3A} receptors may predominate in the CNS, while 5-HT_{3AB} receptors may be more abundant in the PNS. Nevertheless, both 5-HT_{3A} and 5-HT_{3B} subunits, and indeed the other three subunits in this family (5-HT_{3C}–5-HT_{3E}), are widely distributed in




Fig. 5. Association and dissociation curves for [³H]palonosetron using HEK293 cells expressing 5-HT_{3A} and 5-HT_{3AB} receptors. Association was rapid for both 5-HT_{3A} and 5-HT_{3AB} receptors, with maximal levels being reached within 30 min. Dissociation rates were slower, although were faster with antagonists (MDL72222, palonosetron) than agonists (quipazine). Parameters derived from these data are given in Section 3.3.




Fig. 6. [^3H]granisetron and [^3H]palonosetron dissociation curves in 5-HT $_3$ A receptors. Dissociation curves for [^3H]granisetron using HEK293 cells expressing 5-HT $_3$ A receptors using 5-HT (agonist) or MDL72222 (antagonist) are superimposable. However data from [^3H]palonosetron dissociation experiments reveal a clear distinction between agonist and antagonist displacement rates. Data from these curves are shown in Table 1.

many body regions (Holbrook et al., 2009; Niesler, 2011). Our data indicate similar palonosetron K_{d} s at 5-HT $_3$ A and 5-HT $_3$ AB receptors, consistent with previous work showing that competitive antagonists (with one exception, see below) do not show major differences in potency between these two receptor subtypes. This is because the binding site for these compounds is located between two 5-HT $_3$ A subunits, which assemble as part of the 5-HT $_3$ AB pentamer (Lochner and Lummis, 2010; Thompson et al., 2011). The only competitive antagonist that has been identified with distinct affinities at 5-HT $_3$ A and 5-HT $_3$ AB receptors is VUF10166, and the difference in affinities is due to an allosteric binding site at an A + B-interface (Thompson et al., 2012). An allosteric mechanism has also been previously suggested for palonosetron (Moura Barbosa et al., 2010) using computational data, and allosteric binding characteristics have been reported (concave Scatchard plots and Hill slopes of 1.5 (Rojas et al., 2008). Our data showing increased EC_{50} s and decreased maximal responses with increasing concentrations of palonosetron are consistent with a non-competitive mode of action of this compound, i.e. action at an allosteric site. However they are also consistent with an irreversible competitive antagonist, and, given the slow off rates of [^3H]palonosetron, we consider this is the correct interpretation, and that these data reflect the fact that palonosetron does not significantly dissociate from the receptor during these experiments.

We did observe a difference in [^3H]palonosetron dissociation rates depending on the unlabelled ligand used for displacement, with antagonists resulting in more rapid dissociation compared to agonists; similar findings have been previously observed for native 5-HT $_3$ receptors in NG108-15 cells, and 5-HT $_3$ A receptors in HEK293 cells (Bonhaus et al., 1995). These authors suggest that binding of agonists to unoccupied binding sites can increase the receptors affinity for prebound ligands and thereby slow their dissociation. We propose there is a similar mechanism in our experiments. At the start of the dissociation experiments up to five potential binding sites could be occupied by [^3H]palonosetron in 5-HT $_3$ A receptors, with less (1–3) in 5-HT $_3$ AB receptors. Subsequent occupancy of a binding site by unlabelled palonosetron or another competitive antagonist such as MDL72222 would not alter the state of the receptor, while agonist binding likely causes entry into a high affinity desensitized state. Palonosetron, in one or more of the remaining binding sites, would then only dissociate slowly.

Our data also show that both association and dissociation rates are slightly faster for 5-HT $_3$ AB receptors, which may be due to subtle difference in structure of this receptor; it is known, for example, that these receptors are more prone to spontaneous opening (Hu and Peoples, 2008). Our data reveal that agonists have a similar effect in homomeric and heteromeric receptors, providing evidence that there is more than one orthosteric (A + A-) binding site in heteromeric receptors.

In conclusion we have shown that palonosetron binds with similar affinities at 5-HT $_3$ A and 5-HT $_3$ AB receptors. We observed that in both receptor subtypes there is slow dissociation of [^3H]palonosetron, and its rate is ligand-dependent. This slow dissociation, which is particularly pronounced in the presence of agonists, provides a possible additional or alternative explanation for the long lasting therapeutic effects of palonosetron. Our conclusions are strongly supported by a study published during revision of this manuscript (Hothersall et al., 2013). These authors used [^3H]granisetron binding and ELISA to monitor COS-7 cells transfected with 5-HT $_3$ receptors. Their data, obtained predominantly from live cells incubated at a variety of temperatures, indicate that palonosetron acts as a pseudo-irreversible antagonist causing prolonged inhibition due to slow dissociation, with no contribution from endocytosis.

Acknowledgements

This work was supported by a grant from the Wellcome Trust [081925] to SCRL. SCRL is a Wellcome Trust Senior Research Fellow in Basic Biomedical Science. We thank Sergio Cantoreggi and Silvia Sebastiani (Helsinn Healthcare SA, Switzerland) for palonosetron and [^3H]palonosetron and for critical reading of the manuscript. We also thank Mariza Dayrell for excellent technical assistance.

References

- Aapro, M., 2004. Granisetron: an update on its clinical use in the management of nausea and vomiting. *Oncologist* 9, 673–686.
- Blower, P., 1995. A pharmacologic profile of oral granisetron (Kytril tablets). *Semin. Oncol.* 22, 3–5.
- Bonhaus, D.W., Stefanich, E., Lousy, D.N., Hsu, S.A., Eglen, R.M., Wong, E.H., 1995. Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine $_3$ receptors. *J. Neurochem.* 65, 104–110.
- Davies, P.A., Pistis, M., Hanna, M.C., Peters, J.A., Lambert, J.J., Hales, T.G., Kirkness, E.F., 1999. The 5-HT $_3$ B subunit is a major determinant of serotonin-receptor function. *Nature* 397, 359–363.
- Eglen, R.M., Lee, C.H., Smith, W.L., Johnson, L.G., Clark, R., Whiting, R.L., Hegde, S.S., 1995. Pharmacological characterization of RS 25259-197, a novel and selective 5-HT $_3$ receptor antagonist, in vivo. *Br. J. Pharmacol.* 114, 860–866.
- Hirata, T., Keto, Y., Funatsu, T., Akuzawa, S., Sasamata, M., 2007. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. *J. Pharm. Sci.* 104, 263–273.
- Holbrook, J.D., Gill, C.H., Zebda, N., Spencer, J.P., Leyland, R., Rance, K.H., Trinh, H., Balmer, G., Kelly, F.M., Yusaf, S.P., Courtenay, N., Luck, J., Rhodes, A., Modha, S., Moore, S.E., Sanger, G.J., Gunthorpe, M.J., 2009. Characterisation of 5-HT $_3$ C, 5-HT $_3$ D and 5-HT $_3$ E receptor subunits: evolution, distribution and function. *J. Neurochem.* 108, 384–396.
- Hothersall, J.D., Moffat, C., Connolly, C.N., 2013. Prolonged inhibition of 5-HT $_3$ receptors by palonosetron results from surface receptor inhibition rather than inducing receptor internalisation. *Br J Pharmacol.* <http://dx.doi.org/10.1111/bph.12204>. (epub.Apr.15).
- Hu, X.Q., Peoples, R.W., 2008. The 5-HT $_3$ B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT $_3$ receptor. *J. Biol. Chem.* 283, 6826–6831.
- Kelley, S.P., Dunlop, J.L., Kirkness, E.F., Lambert, J.J., Peters, J.A., 2003. A cytoplasmic region determines single-channel conductance in 5-HT $_3$ receptors. *Nature* 424, 321–324.

- Livesey, M.R., Cooper, M.A., Deeb, T.Z., Carland, J.E., Kozuska, J., Hales, T.G., Lambert, J.J., Peters, J.A., 2008. Structural determinants of Ca^{2+} permeability and conduction in the human 5-hydroxytryptamine type 3A receptor. *J. Biol. Chem.* 283, 19301–19313.
- Lochner, M., Lummis, S.C., 2010. Agonists and antagonists bind to an A-A interface in the heteromeric 5-HT₃AB receptor. *Biophys. J.* 98, 1494–1502.
- Lummis, S.C., Sepulveda, M.I., Kilpatrick, G.J., Baker, J., 1993. Characterization of [³H] meta-chlorophenylbiguanide binding to 5-HT₃ receptors in N1E-115 neuroblastoma cells. *Eur. J. Pharmacol.* 243, 7–11.
- Moura Barbosa, A.J., De Rienzo, F., Ramos, M.J., Menziani, M.C., 2010. Computational analysis of ligand recognition sites of homo- and heteropentameric 5-HT₃ receptors. *Eur. J. Med. Chem.* 45, 4746–4760.
- Niesler, B., 2011. 5-HT₃ receptors: potential of individual isoforms for personalised therapy. *Curr. Opin. Pharmacol.* 11, 81–86.
- Price, K.L., Lummis, S.C., 2005. FlexStation examination of 5-HT₃ receptor function using Ca^{2+} – and membrane potential-sensitive dyes: advantages and potential problems. *J. Neurosci. Methods* 149, 172–177.
- Rojas, C., Li, Y., Zhang, J., Stathis, M., Alt, J., Thomas, A.G., Cantoreggi, S., Sebastiani, S., Pietra, C., Slusher, B.S., 2010. The antiemetic 5-HT₃ receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. *J. Pharmacol. Exp. Ther.* 335, 362–368.
- Rojas, C., Stathis, M., Thomas, A.G., Massuda, E.B., Alt, J., Zhang, J., Rubenstein, E., Sebastiani, S., Cantoreggi, S., Snyder, S.H., Slusher, B., 2008. Palonosetron exhibits unique molecular interactions with the 5-HT₃ receptor. *Anesth. Analg.* 107, 469–478.
- Thompson, A.J., Lummis, S.C., 2007. The 5-HT₃ receptor as a therapeutic target. *Expert Opin. Ther. Targets* 11, 527–540.
- Thompson, A.J., Price, K.L., Lummis, S.C., 2011. Cysteine modification reveals which subunits form the ligand binding site in human heteromeric 5-HT₃AB receptors. *J. Physiol.* 589, 4243–4257.
- Thompson, A.J., Verheij, M.H., de Esch, I.J., Lummis, S.C.R., 2012. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors. *J. Pharmacol. Exp. Ther.* 341, 350–359.
- Walstab, J., Rappold, G., Niesler, B., 2010. 5-HT₃ receptors: role in disease and target of drugs. *Pharmacol. Ther.* 128, 146–169.
- Wong, E.H., Clark, R., Leung, E., Loury, D., Bonhaus, D.W., Jakeman, L., Parnes, H., Whiting, R.L., Eglon, R.M., 1995. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT₃ receptors, in vitro. *Br. J. Pharmacol.* 114, 851–859.